RVMD

Revolution MedicinesB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

Probability

Target price

$165.00

+9.0% vs current

Most likely

Base case

Probability

Target price

$132.00

-12.8% vs current

B-

Bear case

Probability

Target price

$105.00

-30.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Primary-source support is adequate for a cautious post-earnings monitoring view because the May 6 8-K confirms the Q1 results release and the 10-Q provides the operating and cash details. The follow-up evidence is still limited: the packet does not provide a concrete earnings surprise, guidance revision, or T+3 analyst revision set, and the peer set is generic for a concentrated RAS oncology developer. News tone remains helped by the prior daraxonrasib clinical update, but missing revision and market-reaction evidence should not be treated as positive confirmation.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-06-30eventRASolve 308 Phase 3 initiation in first-line KRAS G12D NSCLC [#10-Q-2026-05-06]Medium impact

The 10-Q says Revolution expects to initiate RASolve 308, a Phase 3 registrational trial for zoldonrasib in first-line metastatic RAS G12D NSCLC, in the first half of 2026; actual initiation would support the broader RAS(ON) platform beyond daraxonrasib, but the memo should treat this as an execution checkpoint rather than a confirmed value inflection. [#10-Q-2026-05-06]

2026-12-31eventDaraxonrasib regulatory submission path after pivotal RASolute 302 win [#10-Q-2026-05-06]High impact

The Q1 filing says daraxonrasib's Phase 3 RASolute 302 showed median overall survival of 13.2 months versus 6.7 months for chemotherapy with a hazard ratio of 0.40, and management intends to use the dataset in a future NDA/CNPV pathway; regulatory filing progress is now the key de-risking event. [#10-Q-2026-05-06]

2026-12-31catalystQ1 cash runway improved, but burn and filing execution remain the post-earnings focus [#8-K-2026-05-06]Medium impact

Revolution's May 6 8-K confirms the company announced Q1 2026 financial results, and the Q1 filing shows $1.9 billion of cash, cash equivalents and marketable securities at quarter-end plus about $2.1 billion of net proceeds from April 2026 offerings. That funding supports multiple registrational programs, but Q1 net loss was $453.8 million and investors still need evidence that elevated daraxonrasib and zoldonrasib spend converts into filing, approval and launch progress. [#8-K-2026-05-06] [#10-Q-2026-05-06]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology